Combination drug trial for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosis of small cell lung cancer confirmed by biopsy or cell sample
- Cancer has grown back or returned after at least one round of platinum-based chemotherapy (like cisplatin or carboplatin)
- Good overall health and ability to do light daily activities (ECOG score 0–1)
- At least one tumor that can be measured on scans and hasn't been treated with radiation
- Normal organ function in the lungs, heart, liver, kidneys, and blood
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding a new drug, tarlatamab, to the standard treatment durvalumab helps people with limited-stage small cell lung cancer more than durvalumab alone. It is for patients who have already completed chemotherapy and radiation without the cancer growing.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.